Monitoring vaccine safety:  a critical component of every immunisation program

Brotherton, Julia M L; Gold, Michael S

doi:10.5694/j.1326-5377.2008.tb02012.x

Postmarketing surveillance of vaccine safety requires active input from vaccine providers and health care professionals

Human papillomavirus (HPV) vaccines have now been licensed worldwide and at least 26 million doses have been distributed, including more than 3.7 million in Australia.1 Australia was one of the first countries to implement a universal HPV immunisation program for females aged 12–26 years, commencing in April 2007.

1 National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, University of Sydney and The Children’s Hospital at Westmead, Sydney, NSW.
2 Discipline of Paediatrics, University of Adelaide, Women’s and Children’s Hospital, Adelaide, SA.

Correspondence: juliab2@chw.edu.au

1. Therapeutic Goods Administration. Human papillomavirus vaccine (Gardasil). Advice from the Therapeutic Goods Administration. http://www.tga.gov.au/alerts/medicines/gardasil.htm (accessed Jul 2008).
2. McIntyre P, Leask J. Improving uptake of MMR vaccine. BMJ 2008; 336: 729-730.
3. Buttery JP, Madin S, Crawford NW, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust 2008; 189: 261-262.
4. Smith MA, Canfell K, Brotherton JM, et al. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008; July 17 [Epub ahead of print]. DOI: 10.1002/ijc.23633.
5. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination [letter]. Med J Aust 2008; 189: 178.
6. Australian Institute of Health and Welfare. Separation, patient day and average length of stay statistics by principal diagnosis in ICD-10-AM, Australia, 1998–99 to 2004–05. http://www.aihw.gov.au/cognos/cgi-bin/ppdscgi?DC=Q&E=/ahs/principaldiagnosis9899-0405 (accessed May 2008).
7. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001; 20: 410-416.
8. Murphy TV, Gargiullo PM, Massoudi MS, et al; Rotavirus Intussusception Investigation Team. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344: 564-572.
9. US Centers for Disease Control and Prevention. CDC WONDER online database. Vaccine Adverse Event Reporting System (VAERS) request. http://wonder.cdc.gov/vaers.html (accessed Jul 2008).
10. Leask J. Vaccination and risk communication: summary of a workshop, Arlington Virginia, USA, 5–6 October 2000. J Paediatr Child Health 2002; 38: 124-128.

Online responses are no longer available. Please refer to our instructions for authors page for more information.